The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Summary of product characteristics
(2013) · Pharmaceutical Medicine · doi:10.1093/med/9780199609147.003.0027 · Cited by 1,905
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
study, F. T. D., Daly, A. K., International SAE Consortium, Donaldson, P. T., Bhatnagar, P., Shen, Y., Pe'er, I., Floratos, A., Daly, M. J., Goldstein, D. B., et al. (2009) · Nature Genetics · doi:10.1038/ng.379 · Cited by 944
ANDRADE, R., LUCENA, M., FERNANDEZ, M., PELAEZ, G., PACHKORIA, K., GARCIARUIZ, E., GARCIAMUNOZ, B., GONZALEZGRANDE, R., PIZARRO, A., & DURAN, J. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.006 · Cited by 856
Phase II Trial of Sorafenib in Advanced Thyroid Cancer
Gupta-Abramson, V., Troxel, A. B., Nellore, A., Puttaswamy, K., Redlinger, M., Ransone, K., Mandel, S. J., Flaherty, K. T., Loevner, L. A., O'Dwyer, P. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3279 · Cited by 680
Outcome and prognostic markers in severe drug‐induced liver disease†
Björnsson, E., & Olsson, R. (2005) · Hepatology · doi:10.1002/hep.20800 · Cited by 524
Goodman, V. L., Rock, E. P., Dagher, R., Ramchandani, R. P., Abraham, S., Gobburu, J. V. S., Booth, B. P., Verbois, S. L., Morse, D. E., Liang, C. Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2328 · Cited by 501
Kinetics and metabolism of paracetamol and phenacetin.
Prescott, L. (1980) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1980.tb01812.x · Cited by 454
Current Concepts of Mechanisms in Drug-Induced Hepatotoxicity
Russmann, S., Kullak-Ublick, G., & Grattagliano, I. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788803097 · Cited by 412
Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics
Chen, M. H., Kerkelä, R., & Force, T. (2008) · Circulation · doi:10.1161/circulationaha.108.776831 · Cited by 379
Cited by
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Cannarile, M. A., Weisser, M., Jacob, W., Jegg, A.-M., Ries, C. H., & Rüttinger, D. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0257-y · Cited by 1,020
Shyam Sunder, S., Sharma, U. C., & Pokharel, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01469-6 · Cited by 508
Steegmann, J. L., Baccarani, M., Breccia, M., Casado, L. F., García-Gutiérrez, V, Hochhaus, A., Kim, D.-W., Kim, T. D., Khoury, H. J., Le Coutre, P., et al. (2016) · Leukemia · doi:10.1038/leu.2016.104 · Cited by 482
Leise, M. D., Poterucha, J. J., & Talwalkar, J. A. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.09.016 · Cited by 356
Stine, J. G., & Lewis, J. H. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1127756 · Cited by 104
Metadata
- Authors
- Shah, R. R., Morganroth, J., & Shah, D. R.
- Venue
- Drug Safety
- Published
- 2013-04-26
- Volume
- 36
- Issue
- 7
- Pages
- 491-503
- ISSN
- 0114-5916 (ISSN-L)
- 1179-1942
- OpenAlex
- W2065902287
- Cited by
- 252
- References
- 77
- FWCI
- 17.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives. https://app.cochat.ai/papers/10.1007/s40264-013-0048-4
- The paper
- Shah, R. R., Morganroth, J., & Shah, D. R. (2013). Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives. Drug Safety. https://doi.org/10.1007/s40264-013-0048-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.